Skip to content

Telehealth and Remote Blood Pressure

Feasibility and Safety of Incorporating Telehealth Visits Combined With Remote Blood Pressure Monitoring in the Management of Chronic Hypertension in Pregnancy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07356518
Enrollment
60
Registered
2026-01-21
Start date
2026-04-22
Completion date
2026-12-01
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Hypertension in Pregnancy

Keywords

high blood pressure, pre-eclampsia, hypertension during pregnancy

Brief summary

The purpose of this research study is to compare the management of chronic hypertension during pregnancy using telehealth visits with blood pressure telemonitoring and health coaching as compared to standard in person clinic visits. The study involves pregnant woman aged 18-45 who are receiving care for chronic hypertension. Participation in this research study will last until their baby is delivered. The number of in-person clinic visits depends on the participant's treatment assignment. Those assigned to telehealth visits will have telehealth visits alternating with clinic visits every two weeks until the end of pregnancy week 31. Those assigned to telehealth visits will also have five sessions with a health coach via telephone or video from the time of enrollment until the end of pregnancy week 36.

Detailed description

Hypertension (HTN) in pregnancy requires weekly or bi-weekly in-person visits. Telehealth visits with remote blood pressure (BP) telemonitoring may be an alternative to frequent in-person visits improve adherence. However, the feasibility of this approach in pregnancy is lacking and studies are limited on the use of remote BP telemonitoring in chronic HTN (cHTN) during pregnancy. A digital health platform for BP management in pregnant women at risk for preeclampsia (women with cHTN, prior preeclampsia or kidney disease) found fewer admissions for HTN or suspected preeclampsia in the intervention compared to usual care. There is a critical need to investigate the feasibility (willingness and adherence), and safety of this intervention. Without ascertaining the feasibility of telehealth and remote BP monitoring, it remains a challenge to tackle the no-show rates and suboptimal medication adherence during pregnancy. Objectives Aim 1: To determine the feasibility of incorporating telehealth clinic visits with remote BP telemonitoring alternating with in-person clinic visits in the management of cHTN in pregnancy in the clinic by evaluating willingness to enroll, completion rate and adherence versus standard care (in-person clinic visits alone). This working hypothesis is that this approach will be as feasible as standard care. Aim 2: To explore safety outcomes of telehealth clinic visits combined with blood pressure remote telemonitoring alternating with in-person clinic visits in the management of chronic hypertension in pregnant patients in the clinic by measuring the incidence of hypotension, syncope or hospitalization/emergency room visits for severe HTN compared to standard care. The working hypothesis is that this approach will be comparable in safety to standard care.

Interventions

remote visits with participants

BEHAVIORALIn-person visits

standard of care visits with care provider in person

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* prior diagnosis of Chronic hypertension (cHTN) * Pregnant women * Known: documented diagnosis or on antihypertensive medication prior to pregnancy

Exclusion criteria

* Any significant chronic medical or psychiatric illness that, in the investigator's opinion, would prevent participation in the study * Cardiac disorders: cardiomyopathy, angina, Coronary Artery Disease (CAD) * Current substance abuse disorder * Multifetal pregnancy * Participation in another study without prior approval * Plan to deliver outside Atrium Health Wake Forest Baptist * Prior stroke * Severe hypertension * Suspected or known fetal major structural/chromosomal abnormality or fetal demise

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of telehealth with remote BP telemonitoring compared to standard careGestational Week 31willingness to enroll (number of patients enrolled divided by number of patients reached), study completion rate, adherence compared to standard care). Adherence will be defined as taking medication at least ≥80% of the time, recording ≥70% of weekly BP readings in the intervention group only and completing ≥70% of antenatal telehealth/clinic visits.
Safety of telehealth combined with telemonitoring compared to standard careGestational Week 31The number of adverse events reported (hypotension, syncope or hospitalization/emergency room visit for severe HTN

Secondary

MeasureTime frameDescription
Patient satisfaction ScoresGestational Week 31at the end of 31 weeks, each participant will complete a patient research satisfaction survey - Strongly disagree 0, disagree 1, neither agree nor disagree 2, agree 3, strongly agree 4
Clinical team member (Medical Assistant, Nursing staff, Medical Provider, Scheduler) satisfaction ScoresGestational Week 31at the end of 31 weeks, each provider of record for each participant will be invited to complete a research satisfaction survey. Nurses, medical assistants, schedulers at the Comprehensive Fetal Care Center who have participated in the telehealth visit with remote monitoring will be invited to complete a research satisfaction survey - Strongly disagree 0, disagree 1, neither agree nor disagree 2, agree 3, strongly agree 4

Countries

United States

Contacts

CONTACTEjiro Obioma, MBBS MMCi
Ejiro.Obioma@Advocatehealth.org704-355-2000
CONTACTAderonke Adeniyi, MD, MS
aderonke.adeniyi@advocatehealth.org337 713 2278
PRINCIPAL_INVESTIGATORAderonke O Adeniyi, MD, MS

Wake Forest University Health Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026